Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 5, 2004, Pages 465-471

  Bamias, Aristotle ^a,g   Syrigos, Konstantinos ^b   Fountzilas, George ^c   Tzamakou, Eleftheria ^a   Soulti, Kali ^d   Karavasilis, Vasilios ^a   Alamanos, Yiannis ^e   Christodoulou, Christos ^f   Pavlidis, Nicholas ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c AHEPA UNIVERSITY HOSPITAL   (Greece)

^d European Environ Research Institute   (Greece)

^e UNIVERSITY OF IOANNINA   (Greece)

^f Oncology Department   (Greece)

^g NONE   (Greece)

Author keywords

5 fluorouracil; Cisplatin; Gastric cancer; Pharmacokinetics

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG CLEARANCE; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HYPOKALEMIA; HYPOTENSION; KIDNEY TUBULE DISORDER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; SEPSIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 5744242175     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000128870.72525.c7     Document Type: Article

References (27)

1. McKean-Cowdin R, Feigelson HS, Ross KR, et al. Declining cancer rates in the 1990s. J Clin Oncol. 2000;18:2258-2268.
2. Bamias A, Pavlidis N. Systemic chemotherapy in gastric cancer: where do we stand today? Oncologist. 1998;3:171-177.
3. Bamias A, Hill M, Cunningham D, et al. Epirubicin, cisplatin and protracted venous infusional 5-fluorouracil (ECF) for gastroesophageal adenocarcinoma: response, toxicity, quality of life, and survival. Cancer. 1996;77:1978-1985.
4. Lacave AJ, Baron FJ, Anton LM, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol. 1991;2:751-754.
5. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261-267.
6. Ross P, Cunningham D, Scarffe H, et al. Results of a randomized trial comparing ECF with MCF in advanced esophagogastric cancer [abstract]. Proc Am Soc Clin Oncol. 1999;18:1042.
7. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000;18: 2648-2657.
8. Machover D. A comprehensive review of 5-fluorouracil and Leucovorin on patients with metastatic colorectal carcinoma. Cancer. 1997;80: 1179-1187.
9. De Gramont A, Louvet C, Andre T, et al. A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Eur J Cancer. 1998;34:619-626.
10. Cascinu S, Labianca R, Alessandroni P, et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim: a report from the Italian Group for the study of digestive tract cancer. J Clin Oncol. 1997;15:3313-3319.
11. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin 5-FU bolus with bimonthly high-dose leucovorin and 5-fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol. 1997;15:808-813.
12. Louvet C, de Gramont A, Demuynck B, et al. High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. Ann Oncol. 1991;2:229-230.
13. Miller AB, Hoogstrater B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
14. Seymour MT, Patel N, Johnston A, et al. Lack of effect of interferon a2a upon fluorouracil pharmacokinetics. Br J Cancer. 1994;70:724-728.
15. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results of a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039-2045.
16. DeGramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
17. Chi KW, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil and leucovorin chemotherapy. J Clin Oncol. 1995;13:2620-2628.
18. Vokes EE, Ratain MJ, Mick R, et al. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993;11:360-368.
19. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. Eur J Cancer. 1998;34:92-95.
20. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175.
21. Allegra CJ, Grem JL. Antimetabolites. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:432-452.
22. Haaz MC, Fischel JL, Formento P, et al. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. Cancer Chemother Pharmacol. 1996;38:52-58.
23. Johnston PG, Geoffrey F, Drake J, et al. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer. 1996;32A:2148-2154.
24. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 1986;83:8923-8927.
25. Esaki T, Nakano S, Masumoto N, et al. Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer. 1996;65:479-484.
26. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continuous 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000; 83:458-462.
27. Kim YH, Shin SW, Kim BS, et al. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer. 1999;85:295-301.